Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab plus lenvatinib versus docetaxel in metastatic non-small cell lung cancer after platinum doublet chemotherapy and prior i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-08-22